Cancer Archives

News and Trends 3 Oct 2022

Oncopeptides starts European commercialization of myeloma drug in Germany

Swedish biotech company Oncopeptides AB has initiated the commercial launch of Pepaxti (melphalan flufenamide) in Germany. It marks the first market in Europe where the drug is being launched. On August 18, the European Commission granted Pepaxti, in combination with dexamethasone, Marketing Authorization in the European Union and countries in the European Economic Area, for […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Oxford BioTherapeutics enters into antibody agreement with Genmab

Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data. Under the terms of the agreement, Genmab will be responsible for the […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Sierra Space and UC San Diego to develop first stem cell research institute in space

Sierra Space and University of California San Diego, one of the world’s top 15 research universities and a leader in microgravity research, have formed a new agreement with the goal of defining the future of human health care research in space. In a new memorandum of understanding between the two organizations, Sierra Space and UC […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Kling Biotherapeutics doses first patient in advanced solid tumor trial

Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with advanced solid tumors not responding to standard of care. KBA1412 is a first in class fully human anti-CD9 antibody based on an antibody produced by […]

September 29, 2022 - 2 minutesmins - By Jim Cornall

More News! 29 Sep 2022

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Cancer cell growth could be slowed down by removing binding sites for an oncogene, researchers from the University of Helsinki have discovered. They have found a mechanism by which an oncogene commonly activated in cancer patients affects the growth rate of cells. In the future, the findings can help in developing new treatments that could […]

September 29, 2022 - 3 minutesmins - By Liza Laws

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 29 Sep 2022

Positive results from study of drug to treat patients with breast cancer published

Results from a phase 1b study of a drug to treat patients with androgen receptor positive (AR+) metastatic breast cancer (mBC) in China were published yesterday (September 28). Kintor Pharmaceutical Limited, a clinical stage biotech company has developed Pruxelutamide, an oral new generation AR antagonist which has shown promising activity in heavily pretreated AR+ mBC […]

September 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Sep 2022

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […]

September 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Sep 2022

Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors

Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A funding back in March. The investment will allow antibody-drug conjugate (ADC) specialist Pheon to advance its lead ADC program to clinical proof-of-concept and establish of novel ADCs. The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation […]

September 28, 2022 - 3 minutesmins - By Liza Laws

Cleara Biotech closes $2.5M round for senescence treatment

News and Trends 28 Sep 2022

Cleara Biotech closes $2.5M seed financing round to progress senescence treatment

Cleara Biotech has closed a $2.5 million seed financing round that it will use for progress its compounds toward clinical development. The company that develops therapies for treating different pathologies of scarred cellular senescence including late-stage cancer and chronic diseases made the announcement yesterday (September 27). The financing round earlier in the year was led […]

September 28, 2022 - 4 minutesmins - By Liza Laws

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 27 Sep 2022

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […]

September 27, 2022 - 3 minutesmins - By Liza Laws

kai pinkernell glycostem nk cell therapy

Interview 27 Sep 2022

Natural killer cells: a thriving frontier in allogeneic cell therapy

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies. Since their first approvals in 2017, chimeric antigen receptor (CAR)-T cell immunotherapies have showcased the potential of immuno-oncology in providing long-lasting treatments for cancer. This impact was felt in not just the CAR-T cell therapy […]

September 27, 2022 - 6 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Oncopeptides starts European commercialization of myeloma drug in Germany

Estrella and TradeUP merge to become publicly traded company

Oxford BioTherapeutics enters into antibody agreement with Genmab

Sierra Space and UC San Diego to develop first stem cell research institute in space

Kling Biotherapeutics doses first patient in advanced solid tumor trial

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Positive results from study of drug to treat patients with breast cancer published

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors

Cleara Biotech closes $2.5M seed financing round to progress senescence treatment

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Natural killer cells: a thriving frontier in allogeneic cell therapy

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!